Home › Companies › XENE

Xenon Pharmaceuticals

Market cap $3.81B 98.3M shares (10-Q, Nov 5, 2026) × $38.78 close Nov 17, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. Azetukalner MDD Ph3 topline1Q 2027Azetukalner MDD Ph3 topline, 1Q 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Capital (as filed)

Cash
$82.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$868M Sep 30, 2026
Long-term investments
$203M Sep 30, 2026
Operating cash flow
−$90.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.15B cash, runway 2029 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Xenon Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core Xenon Pharmaceuticals (XENE) - Scientific Deep Dive for Azetukalner and Pipeline Products Azetukalner's de-risked Phase 3 epilepsy data and fortress balance sheet justify the enterprise value, with MDD/BPD as speculative upside options.
  2. Buy core UPDATE: Xenon Pharmaceuticals (XENE) - The Filing Window Opens Completed pre-NDA meeting and reaffirmed Q3 filing keep the highest-probability path to 2027 approval intact, with $1.245B cash eliminating dilution risk.
  3. Hold UPDATE: Xenon Pharmaceuticals (XENE) - The NDA Goes In, The Psychiatry Story Gets a Safety Problem NDA submitted on schedule but voluntary enrollment pause across all psychiatry studies due to neuropsychiatric adverse events adds a new risk axis, reducing conviction on upside while epilepsy fortress remains intact.
  4. Hold UPDATE: Xenon Pharmaceuticals (XENE) - The Nav1.7 Ticket Gets Scratched XEN1701 Phase 1 shows clean cardiac profile with adequate Nav1.7 occupancy, improving pain portfolio optionality, but neither upgrade condition (psychiatry event details nor FDA filing acceptance) has been met.
  5. Hold UPDATE: Xenon Pharmaceuticals (XENE) - The Coin Flip Moves Up X-NOVA2 MDD readout pulled into December 2026 but two upgrade conditions remain unmet; epilepsy thesis intact and $1.15B cash provides no financing pressure around the binary readout.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (9 quotes from 5 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

24 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)